Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm)Tuesday, 11 November 2025 - CET (Central European Time, GMT+01:00)

We will explore the technical and operational aspects of process development and manufacturing across the oligonucleotide CMC lifecycle. The focus will be on actionable frameworks demonstrating how Operational Excellence methodologies can enhance internal and external interfaces (e.g., with CDMOs), support effective troubleshooting, mitigate risks, improve efficiencies, and address other critical challenges.

Targeted drug delivery of oligonucleotides to the heart is a rapidly evolving field aimed at improving the precision and efficacy of treatments for cardiovascular diseases. Therapeutic oligonucleotides such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), have the potential to modulate gene expression and protein synthesis for precision medicine approaches for patients with heart diseases. Targeted delivery of oligonucleotides to the heart holds great potential for treating cardiovascular diseases more effectively by maximizing therapeutic benefits while minimizing side effects.

The proper processing of mRNA plays a major role in disease and is regulated by RNA-binding proteins. Inhibiting such proteins can be challenging as the interface between protein and RNA is often devoid of well-defined binding pockets. I will describe our work using stabilized peptides to target such interfaces and highlight how the design of such peptides can be driven by generative AI.

AI in drug discovery has traditionally been built with narrow models that target isolated tasks. But drug development demands end-to-end precision, so this siloed approach sees limited success. AI foundation models represent a breakthrough, as they benefit from breadth of application, synergies between tasks during training and prediction, and scaling of accuracy with data and model size. Brendan will discuss how this tech is transforming AI for drug discovery with applications to ASOs, siRNAs, mRNAs, DNA / RNA editing, and target discovery, and will highlight real-world use across Deep Genomics’ internal programs and collaborations.